Tanager Wealth Management LLP Cuts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tanager Wealth Management LLP cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 928 shares of the medical research company’s stock after selling 80 shares during the quarter. Tanager Wealth Management LLP’s holdings in Thermo Fisher Scientific were worth $483,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Ninety One SA PTY Ltd grew its holdings in shares of Thermo Fisher Scientific by 4.6% during the fourth quarter. Ninety One SA PTY Ltd now owns 14,922 shares of the medical research company’s stock valued at $7,763,000 after buying an additional 653 shares during the last quarter. E. Ohman J or Asset Management AB grew its holdings in shares of Thermo Fisher Scientific by 2.5% during the fourth quarter. E. Ohman J or Asset Management AB now owns 84,863 shares of the medical research company’s stock valued at $44,148,000 after buying an additional 2,087 shares during the last quarter. Verity Asset Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 6.6% during the fourth quarter. Verity Asset Management Inc. now owns 488 shares of the medical research company’s stock valued at $252,000 after buying an additional 30 shares during the last quarter. Rockline Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 5.9% during the fourth quarter. Rockline Wealth Management LLC now owns 1,529 shares of the medical research company’s stock valued at $795,000 after buying an additional 85 shares during the last quarter. Finally, Compass Capital Management Inc. lifted its position in Thermo Fisher Scientific by 6.6% during the fourth quarter. Compass Capital Management Inc. now owns 108,875 shares of the medical research company’s stock valued at $56,640,000 after purchasing an additional 6,738 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 2.2 %

Shares of NYSE TMO opened at $580.63 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The stock has a market cap of $222.09 billion, a PE ratio of 35.13, a P/E/G ratio of 4.06 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $542.95 and a 200 day moving average of $571.55.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.44%.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TMO shares. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research report on Friday, January 10th. Royal Bank of Canada decreased their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Bank of America decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $658.00.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.